Altering the Natural History of Surgical Relapse in Testicular Cancer: Suboptimal Surgery and Pneumoperitoneum (European Urology)

The overall survival for patients with testicular cancer exceeds 95%, and approaches 100% for stage I disease. Given the high probability of cure, clinical investigators have appropriately focused on reducing morbidity and therapy burden without compromising survival in this young patient population. The 2010 Whitmore Lecture entitled Testing the lower bounds of efficacy in testicular cancer addressed this topic and showed how radiation and medical oncologists relied on randomized trials to generate level 1 evidence and establish new treatment paradigms [1].